Sign Up to like & get
recommendations!
0
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.1307
Abstract: Background Many current guidelines rank abatacept (ABA), rituximab (RTX), tocilizumab (TOC), and the TNFi bDMARDs as equal in effectiveness for the treatment of RA, at least as second line therapies. This is mainly based on…
read more here.
Keywords:
drug;
tnfi;
pfizer roche;
effectiveness ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5835
Abstract: Background Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). Objectives To assess the incidence of active TB and the efficacy of TB prevention measures in a large, single-center cohort of patients…
read more here.
Keywords:
roche ucb;
none declared;
pfizer;
abbvie msd ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1179
Abstract: Background Inhibition of interleukin-1 (IL-1) represents a promising treatment option in adult-onset Still’s disease (AOSD). Canakinumab (CAN) is approved for treatment of systemic juvenile idiopathic arthritis (sJIA) since 2013 and recently for AOSD in Europe.…
read more here.
Keywords:
none declared;
treatment;
novartis;
pfizer roche ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.1815
Abstract: Upadacitinib (UPA) is an oral Janus kinase inhibitor approved for rheumatoid arthritis (RA). The safety and efficacy of UPA has been evaluated across a spectrum of patients (pts) with RA in the phase 3 SELECT…
read more here.
Keywords:
mtx;
abbvie;
pfizer roche;
consultant ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.3454
Abstract: A screening program for multimorbidities started in 2014 at the Montpellier University Hospital for primary prevention in patients with chronic inflammatory rheumatic diseases (IRD).The objective of this work was to assess the impact of this…
read more here.
Keywords:
year;
pfizer roche;
roche chugai;